Celltrion's Biosimilar Strategy Includes Simultaneous EMA/FDA Reviews
Executive Summary
Herceptin and Rituxan biosimilar applications expected to reach FDA early next year while EMA review is ongoing; timing could be another test for 351(k) pathway in US.
You may also be interested in...
Pfizer Excludes EU Biosimilar Experience From US Epoetin Application
Even though US product has same cell line and drug product formulation as EU-approved Retacrit, Hospira subsidiary did not bridge to it in its US biosimilar application, meaning US FDA could not consider EU safety and efficacy experience.
Pfizer Excludes EU Biosimilar Experience From US Epoetin Application
Even though US product has same cell line and drug product formulation as EU-approved Retacrit, Hospira subsidiary did not bridge to it in its US biosimilar application, meaning US FDA could not consider EU safety and efficacy experience.
Subcutaneous Rituximab Seems Headed For US FDA Advisory Panel OK
Genentech used pharmacokinetic bridging studies for new route of administration, which uses the enzyme hyaluronidase and is strongly preferred by patients over the IV; firm is seeking indications for follicular lymphoma, diffuse large B-cell lymphoma and chronic lymphocytic leukemia.